IOVANCE BIOTHERAPEUTICS, INC. Noncash Merger Related Costs
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Noncash Merger Related Costs of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2016-03-11
- IOVANCE BIOTHERAPEUTICS, INC. noncash merger related costs for fiscal 2015 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. noncash merger related costs for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- IOVANCE BIOTHERAPEUTICS, INC. noncash merger related costs for fiscal 2013 was $16.66M.
| Period end | Noncash Merger Related Costs 12 month | Noncash Merger Related Costs 12 month as first filed |
|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-11 | |
| 2014-12-31 | $0.00 10-K · filed 2016-03-11 | |
| 2013-12-31 | $16.66M 10-K · filed 2016-03-11 | $16.66M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |